$RYZB News
Last published 2y ago
- 2y agoAUPHAPLSCMPITPTX+5Axonis Therapeutics Announces $115 Million Series A FinancingPR NewswireAxonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an...
- 2y agoAKROAPLSAUPHHRMY+5venBio Raises $528 Million Venture Capital Fund Focused on Life Science CompaniesBusiness Wire- venBio promotes Yvonne Yamanaka, Ph.D. to Partner venBio today announced the closing of venBio Global Strategic Fund V ("venBio Fund V"), its fifth life sciences venture capital fund, exceeding its target and
- 2y agoBMYRYZBBristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical PlatformBusiness WireAdds RYZ101, an IND Engine and Manufacturing Capability, to BMS Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ:RYZB). With the completion
- 2y agoBMYRYZBBristol Myers Squibb Announces Expiration of RayzeBio Tender OfferBusiness WireBristol Myers Squibb (NYSE:BMY) today announced that its previously announced tender offer (the "Offer") to acquire all of the outstanding shares of RayzeBio, Inc. (NASDAQ:RYZB) common stock for a purchase price of
- 2y agoBMYRYZBBristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting PeriodBusiness WireBristol Myers Squibb (NYSE:BMY) and RayzeBio, Inc. (NASDAQ:RYZB) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection with
- 2y agoONCYINCYTNGXRYZB+1Pancreatic Cancer Treatments Poised for Major Advances in 2024PR NewswireUSA News Group - One of the more worrying storylines of 2023 was the rising incidence of early-onset pancreatic cancer. As well, the deadly disease...
- 2y agoDSKEGRPHROVRRYZBKuehn Law Encourages DSKE, RYZB, ROVR, and GRPH Investors to Contact Law FirmGlobeNewswireNEW YORK, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
- 2y agoKRTXDSKERYZBGRCLKuehn Law Encourages KRTX, DSKE, RYZB, and GRCL Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
- 2y agoBMYRYZBBristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBioGlobeNewswireTransaction Brings RayzeBio's Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs to Bristol Myers Squibb's Leading Oncology Franchise Lead Program,
- 2y agoBMYRYZBBristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBioBusiness WireTransaction Brings RayzeBio's Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs, to Bristol Myers Squibb's Leading Oncology Franchise Lead
- 2y agoRYZBRayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswireSAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (NASDAQ:RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today reported financial
- 3y agoRYZBRayzeBio to Participate in Upcoming Investor Conferences in November 2023GlobeNewswireSAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (NASDAQ:RYZB), a biopharmaceutical company developing an innovative radiopharmaceutical pipeline to treat different cancers, today announced that members of
- 3y agoRYZBRayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of DirectorsGlobeNewswireSAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (NASDAQ:RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the appointment
- 3y agoRYZBFDA selects RayzeBio to Participate in the Inaugural CDRP Program to Expedite Commercial Manufacturing Readiness for RYZ101 in GEP-NETsGlobeNewswireSAN DIEGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (NASDAQ:RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the FDA has
- 3y agoRYZBRayzeBio to Present at European Society for Medical Oncology (ESMO) CongressGlobeNewswireSAN DIEGO, Oct. 18, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (NASDAQ:RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced that it will be
- 3y agoRYZBRayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesBusiness WireRayzeBio, Inc. (NASDAQ:RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the closing of its previously announced upsized $358 million
- 3y agoRYZBRayzeBio, Inc. Announces Pricing of Upsized $311 Million Initial Public OfferingBusiness WireRayzeBio, Inc. (NASDAQ:RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the pricing of its upsized $311 million initial public